The Survival Signal That Should Redesign Every RAS-Mutant Pancreatic Trial Running Right Now

Pull up the RASolute 302 dataset and find the survival curve for standard-of-care chemotherapy. The median sits at 6.7 months. For a disease that kills roughly 90% of patients within five years of diagnosis, that number has barely moved in two decades — and every clinical operations team working in second-line pancreatic cancer has built their power calculations, their control arm assumptions, and their site feasibility models around that brutal floor. Now look at the daraxonrasib arm. Median overall survival: 13.2 months. That is not incremental. That is a near-doubling of the survival benchmark that the field has treated as immovable.

The full Phase 3 publication of daraxonrasib in the New England Journal of Medicine on May 7, 2026 — Volume 394, Issue 18 — is not just a clinical milestone for Revolution Medicines. It is a forcing function for trial design across an entire mutation class. Three signals are converging in the oncology development space right now that most people haven’t connected into a single pattern: the collapse of KRAS G12C as the defining target for RAS-mutant pancreatic development, the validation of pan-RAS inhibition as a registrational strategy, and the quiet obsolescence of chemotherapy-only control arms in biomarker-selected pancreatic trials. Call it the RAS Enrichment Reckoning.

The Control Arm Just Became Indefensible

For years, the operational logic of running a second-line pancreatic cancer trial has rested on a clinical assumption so stable it felt like physics: patients on standard-of-care chemotherapy survive roughly six to seven months, and any experimental arm needs to beat that threshold to demonstrate meaningful benefit. Sponsors built their sample size calculations against it. IRBs reviewed it without controversy. The FDA’s Type B meeting templates for pancreatic indications rarely questioned it. RASolute 302 broke that logic in one readout.

The comparison matters at a molecular level, not just a clinical one. Oncogenic RAS mutations appear in 92% of patients with advanced pancreatic ductal adenocarcinoma, based on next-generation sequencing of 27,298 PDAC tissue samples from the FoundationCORE database. Nearly all of those — 91.8% — are KRAS mutations. The field has known this for years, and the development strategy has generally followed KRAS G12C as the tractable target, given the early clinical traction from sotorasib. But KRAS G12C accounts for only a small fraction of the RAS-mutant PDAC population. Daraxonrasib’s pan-RAS mechanism changes the addressable universe entirely — and with it, the patient selection architecture that sponsors have been building since CodeBreaK 100 opened enrollment.

The CodeBreaK 100 Phase 1/2 data for sotorasib in KRAS G12C-mutated PDAC enrolled 38 patients at 960 mg daily — a small but strategically important cohort that set the template for mutation-specific enrichment in pancreatic RAS trials. The lesson sponsors took from that data was essentially: find your mutation subtype, enrich hard, test deep. RASolute 302 inverts that lesson. Enriching for KRAS G12C alone in PDAC now means designing a trial that captures perhaps 3–5% of the eligible RAS-mutant population while ignoring 87% of it. Every sponsor with an active KRAS G12C-only pancreatic protocol needs to open that protocol’s inclusion criteria and reckon with what they built.

What Revolution Medicines Actually Validated

The safety data from RASolute 302 deserves the same operational attention as the efficacy signal. In the Phase 1/2 daraxonrasib cohort, 30% of patients experienced Grade ≥3 treatment-related adverse events, with rash occurring in 88% of all-grade patients and diarrhea in 46% at the 300 mg dose being taken forward into Phase 3. Those are not trivial numbers for site coordinators managing a population that is already compromised from prior lines of gemcitabine-based regimens.

But here is the counterintuitive read: a 30% Grade ≥3 TRAE rate in a previously treated PDAC population — where the disease itself is lethal within months on standard care — may actually represent a favorable risk-benefit calculation that the FDA’s accelerated approval machinery is well-positioned to accept. The agency already granted daraxonrasib both Breakthrough Therapy Designation and Orphan Drug Designation for pancreatic cancer, and has authorized an Expanded Access Protocol. Breakthrough designation for a solid tumor indication with a 6.7-month control arm OS is not a gift — it is the FDA signaling that the unmet need calculus justifies regulatory speed. The Phase 3 NEJM publication now gives that designation a registrational anchor.

What Revolution Medicines actually validated in RASolute 302 is a trial design principle, not just a molecule. Running a biomarker-selected, randomized Phase 3 against chemotherapy in second-line PDAC with an OS primary endpoint — no surrogate, no PFS substitution — produced a clean, defensible dataset that the oncology review division can process without interpretive gymnastics. That design discipline matters enormously in a therapeutic area where the FDA has historically been skeptical of PFS-based approvals given the poor correlation between tumor shrinkage and survival in pancreatic cancer. Sponsors chasing RAS targets in adjacent GI indications should treat RASolute 302 as a design template, not a competitive benchmark.

The Operational Reckoning Sponsors Haven’t Run Yet

The operational implications diverge sharply depending on where you sit in the development ecosystem. For sponsors with active second-line PDAC protocols built on chemotherapy control arms, the RASolute 302 OS data creates an immediate ethical and regulatory pressure: at what point does a 13.2-month median OS in a targeted population make randomization to 6.7-month chemotherapy an IRB-level conversation? The FDA’s guidance on adaptive trial design — including the agency’s framework on seamless Phase 2/3 designs — provides mechanisms to restructure control arms mid-study, but those mechanisms require pre-specification. Sponsors who did not pre-specify an adaptive control arm modification now face a harder conversation.

For CROs running pancreatic cancer portfolios, the RAS Enrichment Reckoning means biomarker screening logistics become a critical path item in a way they have not been before. If 92% of PDAC patients carry actionable RAS mutations, the screening failure rate from biomarker exclusion approaches zero — which sounds like an operational advantage, until you realize that every competing RAS-targeted trial launching in the next 18 months will be fishing from the same patient pool. Site feasibility models that assume broad RAS-mutant eligibility will collide with enrollment timelines that do not account for competitive saturation. Adaptive and seamless trial designs with master protocol architectures — basket and umbrella frameworks that can share screening infrastructure across RAS mutation subtypes — are not just scientifically elegant in this environment. They are operationally necessary.

For technology vendors, the signal is in the NGS data infrastructure. A trial population where 92% of patients carry a targetable mutation sounds easy to screen. In practice, tissue adequacy, turnaround time from community oncology sites, and the gap between academic center NGS capacity and community practice reality will create enrollment variance that no CTMS model has been adequately calibrated for. The sites running RASolute 302 were likely anchor academic centers with established molecular pathology infrastructure. The commercial-phase trials that follow daraxonrasib’s anticipated approval will land at community oncology networks that process far less NGS volume — and site activation timelines will reflect that gap directly in the data.

The FDA’s posture here is understandable but will require extension. Breakthrough Therapy Designation accelerated the RASolute 302 development pathway, and the Expanded Access Protocol signals the agency’s recognition that the survival benefit is real and the unmet need is acute. But the post-approval RWE infrastructure for a pan-RAS inhibitor in a biomarker-selected pancreatic population — how real-world OS will be measured, which comorbidity data will be required, what RWD sources can support label expansion to first-line — remains unsettled. The FDA’s Framework for Real-World Evidence Program provides general methodology principles, but there is no PDAC-specific precedent for pan-RAS post-marketing RWE requirements. Revolution Medicines will be writing that playbook from scratch.

Twelve to eighteen months from now, the first sponsors attempting to run daraxonrasib combination trials — pairing pan-RAS inhibition with immunotherapy or KRAS-specific agents in treatment-naive PDAC — will discover that the RASolute 302 control arm assumption no longer holds even in first-line designs. A 13.2-month second-line OS benchmark cascades backward into first-line power calculations, changes the minimum clinically meaningful difference that ethics committees will accept, and will force FDA reviewers to articulate what survival threshold justifies randomization against a drug that just produced Phase 3 registration data. The next pancreatic cancer trial that launches with a chemotherapy-only control arm and no adaptive modification clause will not survive its first interim analysis review without a protocol amendment — and sponsors that have not pre-specified that flexibility will spend six months negotiating with their IRBs while their competitors enroll.

References

1. New England Journal of Medicine — “Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer,” Vol. 394, Issue 18, May 7, 2026
2. CancerNetwork — “FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC” (daraxonrasib OS 13.2 months vs. 6.7 months chemotherapy)
3. OncLive — “FDA Green-Lights Expanded Access Protocol for Daraxonrasib in Pretreated Metastatic PDAC” (Breakthrough Therapy and Orphan Drug Designation)
4. Revolution Medicines / ASCO GI 2025 — “RAS Mutation Frequency in PDAC,” FoundationCORE database (27,298 samples, 92% RAS mutation rate)
5. Targeted Oncology — “Sotorasib Reveals Anti-Tumor Efficacy in KRAS G12C-Positive Advanced Pancreatic Cancer” (CodeBreaK 100, 38 patients)
6. MedPage Today — “Daraxonrasib Safety Profile in Pancreatic Cancer” (30% Grade ≥3 TRAEs, rash 88%, diarrhea 46%)
7. Friends of Cancer Research — “Seamless Clinical Trial Designs in Rare Cancers: Leveraging Operational and Adaptive Strategies to Accelerate Drug Development”
8. Pancreatic Cancer Action Network — “First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma” (RASolute 302 trial summary)